Li, Changgui

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,504

Development of an inactivated vaccine candidate for SARS-CoV-2

Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 1,434

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., et al. (2020) · Cell

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 748

Development of a Vero cell DNA reference standard for residual DNA measurement in China

Cao, S., Dong, G., Tang, J., Li, J., Liu, J., Shi, L., Li, C., & Wang, J. (2013) · Human Vaccines & Immunotherapeutics

Viral Infectious Diseases and Gene Expression in InsectsScientific Measurement and Uncertainty Evaluation

Cited by 12